DelveInsight’s “PARP Inhibitor Pipeline Insights 2026” report delivers a comprehensive overview of the evolving PARP inhibitor landscape, highlighting the contributions of more than 30 pharmaceutical and biotech companies and over 30 pipeline therapies currently under development. The report provides a detailed analysis of both clinical and preclinical drug candidates, along with insights into therapeutic classification based on product type, development stage, route of administration, and molecular structure. It also sheds light on discontinued or inactive programs within this domain.
Explore DelveInsight’s detailed PARP inhibitor pipeline report and uncover emerging opportunities: https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight
Key Highlights from the PARP Inhibitor Pipeline Report
- On February 19, 2026, AstraZeneca initiated a Phase I/IIa open-label, multi-center study evaluating AZD5305 as a monotherapy and in combination with other anticancer agents in patients with advanced solid tumors.
- On February 18, 2026, EMD Serono launched a Phase II trial assessing the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in patients with BRCA-mutant or HRD-positive epithelial ovarian cancer that progressed following prior PARP inhibitor treatment.
- On February 12, 2026, the Jonsson Comprehensive Cancer Center began a Phase Ib/II study to evaluate the optimal dosing and efficacy of temozolomide in combination with niraparib and atezolizumab in advanced solid tumors and extensive-stage small cell lung cancer.
- The pipeline landscape remains highly active, with over 30 companies developing more than 30 therapies targeting PARP inhibition.
- Key companies driving innovation in this space include TESARO, AstraZeneca, Sun BioPharma, Eisai Co., BeiGene, IMPACT Therapeutics, and Ribon Therapeutics, among others.
- Prominent therapies under development include Vismodegib, Atezolizumab, Olaparib, AZD6738, JPI-547, Rucaparib, Durvalumab, and Cisplatin.
Access in-depth pipeline analysis and stay ahead of emerging breakthroughs: https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight
Overview of PARP Inhibitors
Poly (ADP-ribose) polymerase (PARP) refers to a family of proteins involved in critical cellular processes, particularly DNA repair mechanisms. PARP1 and PARP2 play essential roles in repairing single-strand DNA breaks through the base excision repair (BER) pathway.
The therapeutic relevance of PARP inhibition lies in its ability to enhance the efficacy of certain anticancer treatments. Since its discovery in the 1960s and subsequent research advancements, targeting PARP enzymes has become a promising strategy in oncology, particularly for cancers with defective DNA repair pathways.
PARP Inhibitor Emerging Drug Profile
Pamiparib – BeiGene Pamiparib (BGB-290) is an investigational small molecule inhibitor targeting PARP1 and PARP2. It is currently being evaluated in pivotal clinical trials for recurrent platinum-sensitive and BRCA-mutated ovarian cancers. In addition to monotherapy studies, pamiparib is also being explored in combination with other agents, including BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of multiple solid tumors globally.
Discover the latest innovations and emerging therapies in the PARP inhibitor space: https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight
Insights Covered in the PARP Inhibitor Pipeline Report
The report provides a detailed examination of the PARP inhibitor pipeline, including:
- Profiles of companies actively developing PARP-targeted therapies
- Categorization of pipeline candidates by early, mid, and late-stage development
- Analysis of both active and discontinued therapeutic programs
- Evaluation based on mechanism of action, route of administration, and molecular type
- Assessment of monotherapy and combination therapy approaches
- Review of strategic collaborations, licensing deals, and funding activities shaping future advancements
PARP inhibitor Companies TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others.
PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
Molecule Type
PARP inhibitor Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
Download the full report to gain strategic insights into upcoming PARP inhibitor therapies: https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight
PARP Inhibitor Competitive Landscape and Market Potential
The PARP inhibitor pipeline continues to expand, supported by robust research and development efforts and increasing collaboration between pharmaceutical companies and academic institutions. The growing focus on precision medicine and targeted therapies is expected to further accelerate innovation in this space.
The report also highlights unmet clinical needs, key growth drivers, potential barriers, and future opportunities, providing stakeholders with actionable insights for strategic decision-making.
Scope of the PARP Inhibitor Pipeline Report
- Coverage: Global
- Key Companies: TESARO, AstraZeneca, Sun BioPharma, Eisai Co., BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others
- Key Therapies: Vismodegib, Atezolizumab, Olaparib, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin, and others
- Therapeutic Assessment by product type (monotherapy, combination therapy)
- Analysis across development stages: discovery, preclinical, Phase I, Phase II, and Phase III
Gain a competitive edge with DelveInsight’s PARP inhibitor pipeline insights—access the report now: https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight
About DelveInsight
DelveInsight is a specialized market research and healthcare consulting firm focused on the life sciences and pharmaceutical sectors. The company provides high-quality, data-driven insights and customized research solutions to help organizations make informed business decisions.
With deep industry expertise and a global perspective, DelveInsight empowers clients with real-time intelligence and strategic guidance to stay ahead in an increasingly competitive market landscape.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting